Novavax Q2 2021 Financial Results Earnings Presentation

Novavax reported Q2 2021 earnings with significant progress on its COVID-19 vaccine candidate NVX-CoV2373, including regulatory filings for EUA and confirmed high efficacy in the PREVENT-19 Phase 3 trial. The company confirmed manufacturing guidance of 100M doses monthly by end of Q3 and 150M doses by end of Q4, and announced new agreements with GAVI and the European Commission to expand global distribution.